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ABSTRACT
In solid tumors, cancer stem cells (CSCs) or tumor-initiating cells (TICs) are often found in hypoxic niches.
Nevertheless, the influence of hypoxia on TICs is poorly understood. Using previously established, TIC-
enrichedpatient-derived colorectal cancer (CRC) cultures, we show that hypoxia increases the self-
renewal capacity of TICs while inducing proliferation arrest in their more differentiated counterpart
cultures. Gene expression data revealed macroautophagy/autophagy as one of the major pathways
induced by hypoxia in TICs. Interestingly, hypoxia-induced autophagy was found to induce phosphor-
ylation of EZR (ezrin) at Thr567 residue, which could be reversed by knocking down ATG5, BNIP3, BNIP3L,
or BECN1. Furthermore, we identified PRKCA/PKCα as a potential kinase involved in hypoxia-induced
autophagy-mediated TIC self-renewal. Genetic targeting of autophagy or pharmacological inhibition of
PRKC/PKC and EZR resulted in decreased tumor-initiating potential of TICs. In addition, we observed
significantly reduced in vivo tumor initiation and growth after a stable knockdown of ATG5. Analysis of
human CRC samples showed that p-EZR is often present in TICs located in the hypoxic and autophagic
regions of the tumor. Altogether, our results establish the hypoxia-autophagy-PKC-EZR signaling axis as
a novel regulatory mechanism of TIC self-renewal and CRC progression. Autophagy inhibition might thus
represent a promising therapeutic strategy for cancer patients.
Abbreviations: ATG: autophagy related; BECN1: beclin 1; BNIP3: BCL2 interacting protein 3; BNIP3L:
BCL2 interacting protein 3 like; CQ: chloroquine; CSC: cancer stem cells; CRC: colorectal cancer; HIF1A/
HIF-1α: hypoxia inducible factor 1 subunit alpha; MAP1LC3/LC3: microtubule associated protein 1 light
chain 3; PRKC/PKC: protein kinase C; SQSTM1/p62: sequestosome 1; TICs: tumor-initiating cells.
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Introduction
Colorectal cancer (CRC) is among the most prevalent cancers
worldwide, with more than 1.2 million new diagnoses and
600,000 deaths per year [1], and limited therapeutic options
available. The identification of cancer cells with tumor-
initiating properties, so-called tumor-initiating cells (TICs) or
cancer stem cells (CSCs), has greatly contributed to a better
understanding of CRC and its initiation [2]. TICs represent
a rare subpopulation of cells that not only initiate tumor forma-
tion but also lead to the maintenance and dissemination of the
disease. Additionally, TICs display increased chemoresistance,
demonstrating the necessity of developing TIC-targeted thera-
pies that could prevent disease progression and relapse.
The solid tumor mass is constantly exposed to low oxygen
levels due to excessive cellular proliferation. Hypoxia has been
associated with a more aggressive cancer phenotype, display-
ing increased invasion, metastasis formation, resistance to
chemo- and radiotherapy, and an increased rate of tumor
recurrence [3]. Furthermore, several studies have highlighted
a correlation between hypoxic signaling within tumors and
poor patient prognosis [3]. Interestingly, hypoxic regions in
solid tumors have been shown to overlap with TIC niches [4].
Nevertheless, the mechanisms underlying hypoxia-regulation
of TICs still remain relatively poorly understood.
Cancer cells use macroautophagy/autophagy to facilitate their
survival by maintaining cellular integrity when under strong
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environmental stimuli, such as hypoxia [5,6]. BNIP3 (BCL2
interacting protein 3) and BNIP3L (BCL2 interacting protein 3
like) are two HIF1A (hypoxia-inducible factor 1 subunit alpha)
target genes that mediate the induction of autophagy under
hypoxic conditions, thereby leading to cell survival [5]. The
autophagic machinery depends on the formation of autophago-
somes, which involves two ubiquitin-like conjugation systems
that are formed by the ATG12–ATG5 complex and by
MAP1LC3/LC3 (microtubule-associated protein 1 light
chain 3). The LC3-I form of the protein is lipidated and inserted
into the phagophore (the precursor of the autophagosome)
membrane as LC3-II, which results in the engulfment of the
cargo protein due to its interaction with specific receptors. The
autophagosomes then fuse with lysosomes, where lysosomal acid
proteases promote the degradation of the cargo [7]. Essential
amino acids, such as nucleotides and fatty acids, as well as other
byproducts of degradation, are exported back to the cytoplasm
and serve as an energy source during starvation or hypoxia [7].
EZR is a member of the ezrin-radixin-moesin (ERM) family.
Upon phosphorylation at Thr567, EZR is localized under the
apical membrane, where it connects actin filaments to membrane
proteins. EZR has been implicated in tumor growth by inducing
CRC cell survival, through the regulation of the expression of
inhibitor of apoptosis proteins (IAPs) and BIRC5/survivin [8],
and metastasis dissemination in several types of cancer, including
CRC (reviewed in [9]). In addition, EZR expression in CRC
patients has been shown to be associated with disease progression
and poor survival [10–12]. Interestingly, hypoxia has been linked
to increased EZR expression in pulmonary myofibroblasts.
Increased proliferation and migration of these cells through aber-
rant dysregulation of cytoskeletal proteins can lead to hypoxia-
induced pulmonary arterial hypertension (HPAH), a disease often
associated with heart failure and death [13]. Furthermore, we [14]
and others [15] have recently shown that TICs are one key driving
factor behind the dissemination of metastases. As both TICs and
the EZR pathway are known to be essential for metastatic out-
growth, we hypothesized that EZR signaling may be involved in
the survival of TICs.
In the current study, we have identified autophagy as one of the
major pathways activated inhypoxicTICs. Importantly,wedemon-
strate that phosphorylation of EZR at Thr567, most likely through
PRKCA/PKCα activation, is a vital factor responsible for the
increased self-renewal capacity of TICs. Inhibition of autophagy
led to a reduction in the level of p-EZR and ultimately to reduced
tumor initiation and progression, both in vitro and in vivo. We
hereby describe a novel mechanism by which hypoxia-induced
autophagy drives tumor initiation and progression, and targeting
of this pathway might lead to new therapeutic strategies for CRC.
Results
Hypoxia-induced increase in self-renewal of
patient-derived TICs is maintained over several passages
The isolation and identification of TICs remains a challenging
problem, partly due to the debatable effectiveness of the surface
markers that are typically used for isolating and characterizing
TICs [16–18]. To address these discrepancies, we have previously
established and characterized different CRC spheroid cultures
(SCs), derived both from patient samples and conventional CRC
cell lines. By focusing on functional properties instead of surface
marker expression, we demonstrated that our established SCs
retained many important characteristics of their tumor of origin
and show extensive TIC-like features, such as increased self-
renewal capacity, tumorigenic potential, and chemoresistance
[14,19–21]. These TIC-cultures, as well as their adherent counter-
parts, have been fully characterized by our group in previous
studies [14,19–21].
In the current study, these TIC-enriched spheroid cultures
were used (T6 [stage III], T18 [stage II], and T20 [stage IV],
hereafter referred to as TICs) in order to investigate the effect of
hypoxia in TICs. By exposing TICs and their adherent counter-
parts to 1% oxygen, we observed that hypoxia led to an arrest in
cell division in adherent cells after three days of culture (Fig. S1A).
However, in contrast to their adherent counterparts, TICs did not
exhibit any cell division arrest and even after seven days we could
observe no significant difference in the amount of late apoptotic
cells between the normoxic and hypoxic conditions (Fig. S1B and
S1C). This suggests that TICs might be capable of adapting to
more hypoxic environments, such as those seen in solid tumors.
To further investigate the effect of hypoxia on the growth
behavior of TICs, we assessed the self-renewal capacity of patient-
derived TICs at 1% oxygen by performing limiting dilution assays.
HIF1A protein expression was assessed in TICs exposed to
hypoxic conditions (Figure 1A). Elaborating on research that we
have previously conducted [20,21], we observed that hypoxia
treatment increased the number of spheres in T6, T18, and T20
TIC cultures over the course of several passages (Figure 1B-E).We
could also observe a hypoxia-mediated increase in self-renewal
capacity at various cell doses, down to the single cell level (Figure
1F-H). The extreme limiting dilution analysis (ELDA) software
was used to determine the sphere-forming cell (SFC) frequency of
TICs under normal oxygen levels and under hypoxia. Hypoxia led
to an increase in SFC frequency when compared to normoxia and
this effect was observed for all tested TIC cultures over several
passages (Table S1). Additionally, sphere size (thought to reflect
spheroid proliferation) remained unchanged under hypoxia (Fig.
S1D), even over several passages (Fig. S1E), suggesting that
hypoxic conditions may not affect the proliferation of TICs but
rather increase the self-renewal capacity of these cells.
There are indications suggesting that hypoxia is capable of
regulating the stem cell phenotype via induction of genes involved
in stem cell function, such as POU5F1, NANOG, ALDH1A1, and
SOX2 [22]. As the effect of hypoxia on TIC gene expression
appeared inconsistent (data not shown), we chose to focus on
protein levels and, via the use of a specialized hypoxia chamber
capable of maintaining more consistent O2 levels, analyzed two of
the above-mentioned stem cell markers, POU5F1 and ALDH1A1,
in hypoxic TICs via flow cytometry. We could confirm that
hypoxia increased the expression of both POU5F1 (Figure 1I)
and ALDH1A1 (Figure 1J), further demonstrating that TICs are
self-renewing under hypoxic conditions.
Autophagy is enriched in patient-derived TICs under
hypoxia
To investigate the mechanism underlying the hypoxia-mediated
increase in self-renewal potential of TICs, we performed gene
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expression profiling of patient-derived TIC cultures that had been
maintained under normoxic and hypoxic conditions for seven
days. Principal component analysis (PCA) revealed a clear separa-
tion between clusters derived fromhypoxic and normoxic samples
and showed that three principal components (PCs) are responsible
for 47.6% of total data variability (Fig. S2A). Furthermore, hypoxia
emerged as the primary source of variation in the gene expression
profiling data of primary TICs (Fig. S2B).
In silico functional analysis, using the Ingenuity Pathway
Analysis (IPA) software, predicted the enrichment and activa-
tion of autophagy in TICs derived from patient T18 after 7
d of hypoxic treatment (p-value:5.61E-05; activation
z-score = 2.567) (Table S2). Five expression databases of
autophagy-related genes were also implemented into the
IPA. These were used in order to determine the extent of
autophagy enrichment in the primary TICs. Hypoxia-treated
Figure 1. Hypoxia increases the self-renewal capacity of patient-derived TIC cultures. (A) HIF1A protein expression under normoxic (N) and hypoxic (H) culturing
conditions over 3 d (72 h) and 7 d in T6 TICs. TUBA staining was used as a loading control and HepG2 cells exposed to hypoxia for 24 h were used as a positive
control (+). (B) Representative image of patient T6-derived TICs, cultured under normoxia (N) and hypoxia (H). Scale: 100 µm. (C-H) Self-renewal capacity as
determined by the 1000 cell sphere formation assay (C-E) in T6 (C), T18 (D) and T20 (E) cultures and by the single cell assay (F-G) in T6 (F) and T18 (G) cultures.
Sphere formation was observed over several passages (P). (H) Self-renewal capacity was determined by a limiting dilution assay at multiple cell doses under normoxia
and hypoxia. Results from one experiment using T6 TICs are shown and ELDA was used to assess significance. C-G; Data are representative of at least three
independent experiments. (I-J) Hypoxia induces the expression of stem cell markers. (I) Flow cytometry staining of POU5F1 in T18 TICs under normoxic and hypoxic
conditions and quantification of mean fluorescence intensity (MFI) of POU5F1 in two independent experiments (data normalized to normoxia). (J) Flow cytometry
staining of ALDH1A1 in T18 TICs under normoxic and hypoxic conditions and quantification of mean fluorescence intensity (MFI) of ALDH1A1 in two independent
experiments (data normalized to normoxia). Data are presented as mean ± SD except for F, G, and H, which are presented as a mean with 95% confidence interval,
*p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant.
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T18 and T20 cultures were predicted to be enriched for
autophagy-related genes, while T6 TICs were predicted to
display a lower degree of enrichment (Figure 2A).
An analysis of the gene expression profiling data demonstrated
that several autophagy-related genes, such as HIF1A, BIRC6
(baculoviral IAP repeat containing 6), and UVRAG, a well-
known activator of the BECN1-PtdIns3K complex, were upregu-
lated in hypoxia-treated TICs (Figure 2B). Most importantly, we
observed a clear upregulation of BNIP3 and BNIP3L, two key
genes involved in the initiation of autophagy under hypoxia and
target genes of HIF1A [5]. This enrichment of BNIP3 and BNIP3L
was validated in our three hypoxia-treated patient-derived TIC
cultures (Figure 2C). As expected [5,23], the expression of BNIP3
and BNIP3L decreased in stable HIF1A knockdown cultures
under hypoxia, demonstrating that these genes are HIF1A-
regulated (Fig. S2C). We next investigated the clinical relevance
of BNIP3 and BNIP3L in the context of CRC. Using TMA’s of
colorectal tumor tissue and their paired normal counterparts, we
were able to demonstrate an increase in BNIP3 and BNIP3L
protein levels in tumor samples (Figure 2D,E). BNIP3 expression
has already previously been shown to be increased in tumor
samples derived from other cancer types, such as non-small-cell
lung cancer and breast cancer [23–25]. Its expression has also
been associated with hypoxia [23,24], an invasive phenotype [25],
and poor survival prognosis [24]. Using publicly available data-
sets, we were able to show that high expression of BNIP3L corre-
lated with shorter disease-free survival time (Figure 2F and Fig.
S2D). Our findings strongly suggest that both BNIP3 and BNIP3L
could potentially be clinically relevant in CRC patients, although
further validation studies are necessary to reinforce our
observations.
We also examined the presence of LC3A-coated autophago-
somes in our samples. An increased level of autophagosomes
was observed in hypoxic primary TICs (Figure 3A,B upper
panels, the scramble [scr] conditions under hypoxia and nor-
moxia, and Figure 3C-E for quantification). These findings
corroborate our gene expression profiling data and confirm
the activation of autophagy in TICs under hypoxic conditions.
Blocking key autophagy players reverses
hypoxia-mediated effects in patient-derived TICs
BECN1, ATG5, BNIP3, and BNIP3L are key genes involved with
the autophagic machinery [7]. To evaluate to what extent autop-
hagy is associated with the hypoxia-mediated phenotype of
TICs, we inhibited autophagic flux in our patient-derived TIC
cultures by targeting ATG5, a gene required for the maturation
of autophagosomes [26] (Fig. S3A and S3B). Interestingly,ATG5
knockdown considerably decreased the number of autophago-
somes in hypoxic samples, further highlighting the induction of
autophagy in hypoxic TICs (Figure 3A-E). Furthermore, the
expression of autophagy substrate protein SQSTM1/p62 was
reduced in all three primary TIC cultures after hypoxic treat-
ment, and reversed by the addition of chloroquine, indicating
that hypoxia increases the autophagic flux in primary TICs
(Figure 3F). Additionally, ATG5 knockdown led to an accumu-
lation of SQSTM1, demonstrating the inhibition of autophagic
flux inATG5 knockdown TICs (Figure 3G).We also assessed the
role of other members of the autophagic cascade and observed
reduced formation of autophagosomes (Figure 3H) after stable
knockdowns of BECN1, BNIP3, and BNIP3L (Fig. S3C-E).
Altogether, our results suggest that inhibition of the autophagic
flux partially reverses the hypoxia-induced phenotype in TICs.
Hypoxia-induced autophagy phosphorylates EZR through
PRKCA in colon TICs
In order to investigate the mechanism underpinning autop-
hagy-mediated regulation of hypoxia-treated TICs, we carried
out high-throughput ELISA-based phospho-protein antibody
arrays. We found that EZR phosphorylation on Thr567 was
significantly upregulated under hypoxia. Conversely, inhibi-
tion of autophagy significantly reduced Thr567 phosphoryla-
tion (Table S3). First, we aimed to validate this data by
evaluating the expression of EZR, as well as its Thr567 phos-
phorylated form, in primary colon TICs. Hypoxia treatment
led to an increase in EZR phosphorylation in T18 (Figure 4A)
and T6 (Figure 4B) TICs. We next assessed the phosphoryla-
tion of EZR upon ATG5 silencing. As suggested by the phos-
phoarray data, we observed a decreased level of
phosphorylation in autophagy-inhibited patient-derived TIC
cultures (Figure 4C,D). Similarly, p-EZR was reduced when
other autophagy-related genes were silenced, such as BNIP3
(Figure 4E), BNIP3L (Figure 4F), and BECN1 (Figure 4G).
This clearly demonstrates that the autophagic pathway is
involved in EZR activation. EZR has been shown to be acti-
vated by numerous different kinases, such as EGFR (epider-
mal growth factor receptor), PRKC, and IGF1R (insulin
growth factor 1 receptor) [9]. We first focused on EGFR as
our array data suggested it to be highly upregulated in
hypoxic T18 TICs and because blockage of the EGFR signal-
ing pathway is already a well-established treatment method in
late-stage CRC patients. However, when EGFR expression was
reduced via siRNA, we did not observe any change in p-EZR
(data not shown). Following this, we assessed the involvement
of PRKCA, which has been previously shown to interact with
EZR [27] and whose activity in the phosphoarray data seemed
to more closely resemble that of EZR (data not shown). In line
with our phosphoarrays, we observed the activation of PRKC
under hypoxic conditions, which seemed to correlate with
EZR phosphorylation (Fig. S4A). In addition, EZR phosphor-
ylation at Thr567 was reduced in hypoxic T6 and T18 TIC
cultures after PRKCA knockdown (Figure 4H,I, gene expres-
sion levels of PRKCA were reduced by 70% after siRNA
transfection of TICs). Specific inhibition of PRKC-mediated
EZR phosphorylation at Thr567 (NSC668394 and
NSC305787), as well as general inhibition of PRKC
(Go6976), were also able to reduce hypoxia-driven activation
of EZR (Figure 4J-L). Altogether, these results suggest that
PRKCA might be the kinase responsible for the phosphoryla-
tion of EZR under hypoxia.
As a follow-up, we looked further into the downstream signal-
ing of EZR, which we hoped might explain our pro-self-renewal
TIC phenotype. EZR has been associated with a number of differ-
ent downstream signaling pathways, including the AKT, MAPK/
ERK, and MAPK14/p38 pathways [28–30]. While AKT and
MAPK/ERK pathways remained unchanged under hypoxia and
after EZR inhibition (Fig. S4B, and data not shown), MAPK14
4 K. QURESHI-BAIG ET AL.
Figure 2. Autophagy is enriched in patient-derived TIC cultures exposed to hypoxia. (A) Bar plots showing the statistical significance (-log[p-value]) of
autophagy in TICs derived from patients T6, T18 & T20 after 7 d of hypoxic treatment, as determined by IPA functional analysis using a combination of five
different autophagy databases (see Material and Methods). Statistical threshold (red line) is set at -log(p-value) = 1.3. (B) Standardized expression of key
autophagy genes in patient T18-derived TICs. Heat map of up- or downregulation of selected key autophagy genes in T18 TICs after 7 d treatment with
hypoxia (H) and normoxia (N). Gene expression levels of BNIP3 and BNIP3L, targets of HIF1A, and key genes involved in the initiation of autophagy in hypoxia.
Red indicates upregulation and blue downregulation. Significance is based on adjusted p-values (or FDR) of hypoxia-normoxia comparison after 7 d (C) Gene
expression levels of BNIP3 and BNIP3L in T6-, T18-, and T20-derived TICs after 72 h of hypoxia (H) and normoxia (N). Representative figure of at least three
independent experiments per TIC culture. Data are presented as mean ± SD, ***p < 0.001. (D-E) Immunohistochemical staining of BNIP3 (D) and BNIP3L (E) on
paired CRC tissue microarrays. Matched tumor (CRC) and control mucosa (N) samples were scored for the intensity of BNIP3 (n = 62 matched samples) and
BNIP3L (n = 63 matched samples) positive cells, ranging from 0 (= no signal) to 2 (= strong signal). Scale bar: 200 μm. Data are presented as mean ± SD,
***p < 0.001. Paired t-tests were used to assess the significance between tumor and normal counterpart tissues in D and E. (F) Relapse-free CRC patient
survival, according to BNIP3L expression in the publicly available dataset GSE14333, *p < 0.05.
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phosphorylation increased under hypoxia and was reversed after
EZR inhibition (Fig. S4C). Interestingly, MAPK14 MAPK path-
way activation has already been associated with increased TIC
chemoresistance and self-renewal capacity [31]. Nevertheless, as
MAPK14 is also a direct target of hypoxia, further experiments are
needed to clearly determine the involvement of MAPK14 in the
hypoxia-autophagy-PRKC-EZR pathway.
Inhibition of autophagy reverses the hypoxia-mediated
self-renewal capacity of patient-derived TICs
To further determine the role of autophagy in the aggressive
phenotype of colon TICs, we investigated the effects of autop-
hagic inhibition on the self-renewal capacity of patient-derived
TICs under hypoxic conditions. To do this, we carried out
Figure 3. Hypoxia induces the formation of autophagosomes and autophagy inhibition via ATG5 knockdown decreases the number of autophagosomes in hypoxic
TICs. (A-B) Control (scr) and ATG5-defective (shATG5) T6, T18 and T20-derived TICs were transfected with GFP-LC3 and cultivated in (A) normoxic and (B) hypoxic
environments (overnight, at 0.1% oxygen level, see Material and Methods). Autophagosomes (green dot-like structures) were visualized by confocal microscopy.
Images represent three independent experiments, scale bar: 5 µm. (C-E) Quantification of the number of autophagosomes in control (scr) and ATG5-defective
(shATG5) patient-derived (C) T6, (D) T18 and (E) T20 TICs cultured under normoxia or hypoxia. (F) SQSTM1 protein expression in normoxic (N) and hypoxic (H) TICs
after the addition of chloroquine. Western blot images are representative of two independent experiments. (G) SQSTM1 protein expression in ATG5-defective (+) and
scramble (-) TICs under normoxia (N) or hypoxia (H). Western blot images are representative of two independent experiments. (H) Detection and quantification of
autophagosomes in TICs after BECN1, BNIP3, and BNIP3L knockdown. For the quantification of autophagosomes (C-E and H), ten cells were counted for each condition
and the average number of autophagosomes was reported. Statistically significant differences are shown as *p < 0.05, **p < 0.01, ***p < 0.001. Figures displayed are
representative figure of at least two independent experiments per TIC culture for C-E and H. In H, * represents statistical analysis between normoxia and hypoxia,
whereas # represents the statistical analysis between the hypoxic scramble condition and the shBNIP3, shBNIP3L, and shBECN1 conditions.
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single-cell sphere formation and 3D colony formation assays.
Inhibition of autophagy by stable knockdown of ATG5 did not
seem to have a significant effect on sphere formation capacity
under normal oxygen conditions. However, inhibition of
autophagy did lead to a significant decrease in sphere formation
capacity in hypoxic TICs, thereby reversing the hypoxia-
mediated phenotype of TICs on a single cell level (Figure 5A).
The sphere size, a well-established measure of the proliferation
Figure 4. Hypoxia induces EZR phosphorylation in an ATG5-dependent manner. (A-B) Phosphorylation of EZR at Thr567 under normoxic (N) and hypoxic (H) culturing
conditions in (A) T18 and (B) T6 TICs. Data are representative of at least four independent experiments. (C-D) Activation of EZR after ATG5 knockdown in (C) T18 and
(D) T6 TIC cultures after 16 h of hypoxia. Quantification was performed based on four independent experiments (mean ± SD) and is shown on the right side of the
respective graph. *p < 0.05. (E-G) Activation of EZR following silencing of (E) BNIP3 (F) BNIP3L and (G) BECN1 after 16 h of hypoxia in T18 TIC cultures. Data are
representative of three independent experiments and similar results were obtained for T6 TICs. (H-I) Effect of PRKCA siRNA on EZR phosphorylation under normoxia
and hypoxia (16 h) in (H) T6 and (I) T18 TICs. Data are representative of two independent experiments per TIC culture. (J-K) Effect of NSC305787 and NSC668394, two
chemical inhibitors of PKC-mediated EZR phosphorylation in hypoxic (16 h) T6 TICs. Data are representative of at least two independent experiments. (L) Effect of
Go6976, a chemical inhibitor of PRKC, on the phosphorylation of EZR in hypoxic (16 h) T6 TICs. Data are representative of three independent experiments.
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rate, was not affected, as both knockdown and control condi-
tions produced similarly sized spheres under both normoxia
and hypoxia (Fig. S4D). In addition, and in agreement with our
previous experiments, 3D colony formation potential of
hypoxia-treated primary TIC cultures was decreased after
ATG5 inhibition (Figure 5B). We further validated these find-
ings by performing shRNA-mediated silencing of BNIP3,
BNIP3L, and BECN1 – all crucial genes involved in the initiation
Figure 5. Inhibition of autophagy reverses hypoxia-mediated phenotype in patient-derived TICs. (A) Sphere-forming capacity (%) was determined by carrying out
single cell assays in ATG5-defective (shATG5) and control (scr) T18 TICs under 10 d of normoxia (N) and hypoxia (H). Representative figure of 4 independent
experiments. Data are presented as mean with a confidence interval of 0.95, p-value calculated using a chi-square test. (B) Colony numbers under hypoxia (H) for
control (scr) and ATG5-defective (shATG5) TICs derived from patients T6, T18, and T20. Data are presented as a representative figure of at least 2 independent
experiments per TIC culture, mean ± SD, ***p < 0.001. (C-E) Colony numbers after 10–14 d under normoxia (N) and hypoxia (H) for control (scr) and BECN1-defective
(shBECN1) TICs derived from patients (C) T6, (D) T18 and (E) T20. (F-G) Colony numbers after 10–14 d of hypoxia for small inhibitor of EZR (NSC668394) treated (F) T6
and (G) T18 TICs. (H-I) Colony numbers after 10–14 d of hypoxia and Go6976 treatment for (H) T6 and (I) T18 TICs. For 3D clonogenic assays of C-I, data are
representative of at least 3 independent experiments, mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001.
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of autophagy. Similar to what we saw with ATG5, silencing
BNIP3, BNIP3L, or BECN1 decreased TIC colony formation
under hypoxic conditions (Figure 5C-E and Fig. S4E-G).
Collectively, these results show that a stable inhibition of autop-
hagy allows for the reversal of hypoxia-mediated self-renewal of
colon TICs.
As mentioned previously, we observed EZR phosphoryla-
tion in colon TICs upon hypoxic treatment. This effect was
ATG5-dependent and most likely due to PRKC kinase activ-
ity. To further understand the role of the PRKC-EZR activa-
tion loop in the behavior of TICs, we performed 3D colony
formation assays after inhibition of PRKC and EZR. First, we
tried to lower the expression of EZR via a number of different
gene knockdown techniques such as shRNA, siRNA, and
CRISPR-Cas9. Unfortunately, none of these techniques
allowed us to achieve a consistent and significant reduction
in protein levels of EZR in TICs (Fig. S5A-F). We then
switched to small molecule EZR inhibitors [32], which have
recently been described to be specific for EZR over the other
ERM proteins [32] and that did not induce cell death in our
TIC cultures (Fig. S6G). Importantly, we found that most
TICs, in comparison to differentiated adherent cells, almost
exclusively express EZR, with MSN (moesin) being expressed
to a much lesser degree compared to adherent cells and RDX
(radixin) expression being completely absent (Fig. S5H-J).
Therefore, taken altogether, the observed effect of the small
inhibitors described below is very likely to be due to their
direct effect on EZR. In both tested cases, inhibition of EZR
(Figure 5F,G, and Fig. S5K) and PRKC (Figure 5H,I) led to
a drastic reduction in hypoxia-induced self-renewal capacity
of TICs. These results suggest that hypoxia-induced autop-
hagy leads to PRKC-EZR activation, which subsequently
drives self-renewal of TICs through the activation of other
downstream players.
Inhibition of autophagy impairs tumorigenic properties
of TICs in vivo
Chloroquine (CQ) is a broad inhibitor that blocks late autophagic
events by preventing the fusion of autophagosomes with lyso-
somes, preventing their subsequent degradation. We observed
reduced tumor growth and weight in immune-deficient CQ-
treated mice (Figure 6A,B), further suggesting that autophagy
inhibition is a potentially promising avenue of CRC treatment.
Nevertheless, as off-target effects of chloroquine may also
be responsible for this observed effect, we analyzed the
tumorigenicity of patient-derived TICs in immune-
deficient mice following shRNA-mediated silencing of
ATG5. Silencing of the ATG5 gene in subcutaneously
injected immune-deficient mice resulted in tumors of smal-
ler weight and lower volume (Figure 6C-E, and Fig. S6A).
ATG5 levels remained low in extracted xenografts and cor-
related with an increase in SQSTM1 expression (Figure 6D
and Fig. S6B), suggesting that the suppression of the autop-
hagic pathway was responsible for reduced in vivo tumor
growth. Additionally, in line with our in vitro data, p-EZR
expression was significantly reduced in extracted xenografts
after ATG5 silencing (Figure 6F), indicating that the path-
way is also active and relevant as a regulatory mechanism of
in vivo tumor initiation. Furthermore, we aimed to deter-
mine whether inhibition of autophagy resulted in reduced
TIC tumor-forming capacity. Serial transplantation experi-
ments, which are considered to be the gold standard for
evaluating TIC capacity, were carried out in order to study
the impact of autophagy inhibition on in vivo self-renewal
capacity. Cells derived from primary tumors were serially
transplanted in secondary xenografts. Strikingly, low dose
injections of ATG5-silenced cells into secondary recipient
mice led to reduced tumor incidence, thereby demonstrating
impaired in vivo self-renewal capacity (Figure 6G). Of note,
as with the primary xenograft, we also observed a reduction
in tumor weight in ATG5-silenced mice (Fig. S6C).
We next wondered whether the identified signaling path-
way may also be of relevance in human patients. For this, we
used human CRC samples and stained tumor sections for
HIF1A, MAP1LC3A, and p-EZR. Our observations showed
that hypoxic regions (with high HIF1A expression) are also
highly positive for LC3A, a well-known marker of autophagy.
In addition, IHC image analysis suggested that p-EZR stain-
ing is often located in hypoxic/autophagic regions of the
tumor (Fig. S7A for controls and S7B). To further validate
this data we carried out immunofluorescence stainings on
primary CRC tissues (Figure 7A and Fig. S7C for patient
characteristics including TNM staging as well as the HE
staining) and analyzed the co-localization of the different
members of the identified signaling pathway in human
TICs (herein defined as POU5F1-positive cells). Based on
LC3A, BNIP3L, and CA9 stainings we were able to verify
their presence in POU5F1-positive cells. Additional experi-
ments also confirmed that p-EZR was present in human TICs
and co-localized with LC3A, BNIP3L, and CA9, suggesting
that the hypoxia-autophagy-EZR pathway is active in the
same population of human TICs (Figure 7A,B). Taken
together, our results suggest that the hypoxia-autophagy-
EZR pathway is activated in human primary CRC tissues
and is clinically relevant. By extension, targeting the hypoxia-
autophagy-EZR axis may, therefore, lead to new therapeutic
interventions.
Discussion
Over the last couple of years, oxygenation status of the tumor
has been reported to be tightly linked to aggressive behavior.
This is, in part, explained by the fact that hypoxia is the major
driving force behind tumor vascularization and invasion
[33,34]. Moreover, hypoxic regions within a tumor have also
been found to overlap with cancer stem cell niches [35] and
hypoxia itself has been shown to enhance self-renewal in
embryonic stem cells [36]. Similarly, hypoxic conditions con-
tribute to increased self-renewal of breast and glioma TICs
[35,37,38]. In regards to CRC, Yeung and colleagues used
TICs derived from CRC cell lines to demonstrate that TICs
form more undifferentiated colonies under hypoxic condi-
tions and more differentiated structures under normal oxygen
levels [39]. We were interested in evaluating how hypoxia
influences primary patient-derived TIC cultures by taking
advantage of our recently established cultures [19]. Our
results, reported here, strongly suggest that hypoxia is
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Figure 6. ATG5 deficiency limits tumor initiation and progression in vivo. (A) In vivo tumor growth after subcutaneous injection of 10,000 T18-derived TIC cells and
subsequent intraperitoneal treatment with either CQ or PBS (n = 12 tumors per group). Data are presented as means tumor volumes (mm3) ± SEM. (B) T18 tumor
weight after treatment with CQ or PBS, respectively. Data are presented as mean tumor weights (mg) ± SEM. (C) In vivo tumor growth after subcutaneous injection of
10,000 T20-derived TIC cells with/without stable knockdown of ATG5, n = 5 mice/group. (D-E) Tumor (D) growth and (E) weight in immune-deficient mice (NSG
mice), 8 weeks after subcutaneous injection of 10,000 cells derived from primary T18 TICs, following a stable knockdown of ATG5 or respective control vector; n = 6/
group. A representative ATG5 protein expression of extracted T18-derived xenografts is shown. All data are shown as mean ± SEM. Two-way ANOVA followed by the
Tukey post-hoc test was used to test for statistical significance in A, C and D. Paired t-tests were used to assess significance in B, and E. *p < 0.05, ***p < 0.001 (F)
p-EZR immunofluorescence staining in extracted xenograft tumors from (D). Scale bar: 100 µm. Representative images are shown (left panel) as well as the
quantification of p-EZR-positive area (right panel). Four mice out of the six from (D) were used, as the remaining two were used in (G). Data are presented as mean ±
SD, *p < 0.05. (G) Serial in vivo limiting dilution experiment with T18 TICs, following stable knockdown of ATG5 or the corresponding control vector. After an initial
round of xenotransplantation, two extracted tumors (from mice appearing in [D]) were dissociated and different cell doses (100, 250 and 500 cells) were
subcutaneously injected into secondary recipient NSG mice. Secondary tumor incidence was evaluated after 12 weeks. Statistical significance was assessed with a Chi-
square test ** p < 0.01. (H) Potential mechanism of action. Hypoxia within a solid tumor leads to activation of autophagy, especially in TICs. Kinases, such as PRKCA,
are activated and further induce phosphorylation of EZR on Thr567 in TICs. EZR, most likely through MAPK14/p38 activation, leads to increased self-renewal capacity
of TICs in vitro and in vivo.
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a promoter of self-renewal in patient-derived TICs. This
hypoxia-induced phenotype may help to explain why hypoxia
has been linked with increased disease aggression and poorer
prognosis [40].
To date, the exact mechanism through which hypoxia, via
HIFs and/or other regulators, influences the fate of colon
TICs has not yet been fully elucidated. Recently, we have
shown that hypoxia enhances the self-renewal capacity of
colon TICs through a MIR210 (microRNA 210)-induced gly-
colytic phenotype that correlates with enhanced tumorigeni-
city and TIC self-renewal [20,41]. In the current study, we
observed the enrichment and increased activation of autop-
hagy in patient-derived TIC cultures after hypoxia treatment.
We show that the inhibition of autophagy (achieved by
knocking down the major autophagic genes BECN1, ATG5,
BNIP3, and BNIP3L) reverses the increased self-renewing
Figure 7. The relevance of the hypoxia/autophagy/EZR pathway in human TICs. (A) Immunofluorescence staining and colocalization in human tumor tissues (from six
patients) for CA9 (a downstream target of HIF1A), BNIP3L, MAP1LC3A, p-EZR, and POU5F1 (refer to Fig. S7 for patient characteristics including TNM staging and HE
stainings). The specificity of all used antibodies was carefully validated (please see Material and Methods and Supplementary data). Scale bar: 100 µm. (B) Staining
correlation in human CRC tissues. Measures were standardized (z-score) for each patient. Dot colors indicate different patients. A repeated measure correlation test
was performed in order to account for the within-individual association of paired measures (using the rmcorr package in R; see Material and Methods). The rmcorr
r coefficient and the Holm adjusted p-values are reported on each plot.
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capacity of patient-derived TICs under hypoxia. Additionally,
we provide evidence that impaired autophagy leads to reduced
tumor initiation and growth in vivo. Along these lines, inhibi-
tion of the autophagic flux has also been shown to decrease
the survival of pancreatic [42] and liver [43] TICs under
oxygen-deprived conditions and autophagosomes have been
discovered to exist in hypoxic tumor regions [44]. In addition,
hypoxia-induced autophagy is also involved in immunoresis-
tance mechanisms, as it has been shown to result in impaired
T-lymphocyte-mediated cell lysis of tumor cells and reduced
NK-mediated killing efficiency [45,46].
It is becoming more generally accepted that the autophagic
machinery contributes to TIC survival in response to changes in
the tumormicroenvironment.BECN1, involved in the initiation of
the autophagic pathway, has been shown to promote the survival
of breast CSCs (but not bulk cancer cells) and to contribute to their
tumorigenicity in vivo [47]. ATG4A, another key player in the
autophagy pathway was shown to be involved in the maintenance
of breast TICs and to regulate breast cancer cell tumorigenicity
in vivo [48]. Autophagy has been related to therapy resistance in
cancer cells in general and more specifically in TICs [49–51]. In
colon TICs, autophagy has been shown to promote resistance to
paclitaxel by inhibiting apoptosis and upregulating CDX1 (caudal
type homeobox 1) [50]. Thus, autophagy inhibitors could poten-
tially be employed to increase the sensitivity of TICs to anti-cancer
therapies. In addition, a recent study showed thatATG7 deficiency
in intestinal epithelial cells prevents the formation of pre-
cancerous lesions in APC± mice by enhancing anti-tumor
responses [52]. As such, therapies targeting the autophagy path-
way may lead to multiple beneficial effects, such as increased
tumor cell death and tumor sensitization to immunotherapies.
We identified EZR, a member of the ERM proteins, as
a potential candidate involved in the hypoxia-induced autophagy-
mediated phenotype of colon TICs. In line with our data, phos-
phorylation of EZR at Thr567 by PRKC has been shown to be
highly regulated during the osteosarcoma metastasis [53].
However, EZR could also potentially be activated through the
activity of other kinases. Thr567 phosphorylation of EZR by Rho
kinase has been linked to invasive hepatocellular carcinoma and
poor in vivo survival [54]. Similarly, increased phosphorylation of
EZR at the Thr567 site has been observed in CRC-derived liver
metastasis [8]. Phosphorylation of EZR at Thr567 is known to
occur downstreamof IGF1R signaling inCRC samples, suggesting
that it may play a key role in the regulation of cell survival in
IGF1R-dependent CRC cells [8]. We identified a number of other
activated proteins in the phospho-array data, which might also
play an important role in the hypoxia-induced phenotype of TICs.
For example, we could observe phosphorylation of HDAC6 under
hypoxia, which was reversed after efficient ATG5 knockdown
(data not shown), suggesting that epigenetic modifications might
also play a role in the hypoxia-induced phenotype of TICs. Along
similar lines, a recent study has highlighted the role of HDAC6 as
an important regulator of pluripotency markers and stemness in
TICs [55]. Further research, however, is necessary in order to
better unravel the mechanisms that underpin hypoxia-induced
self-renewal of TICs.
In conclusion, we highlight autophagy as a potential
mechanism underlying the hypoxia-mediated increase in self-
renewal of patient-derived TIC cultures, an effect that is at
least partially driven in a PRKCA-EZR-dependent manner.
Taken together, hypoxia can be seen as a potential regulator
of both autophagy and TIC behavior. Our findings demon-
strate that increasing our understanding of the functional
relevance of autophagy within the tumor microenvironment,
as well as targeting autophagy within tumors, represents
a promising therapeutic avenue that may allow for the evasion
of drug resistance, thereby strengthening the effects of other
anticancer therapies.
Materials and methods
Patient, tissue microarrays, and staining
Human colon tissue samples were collected by the Laboratoire
National de Santé (LNS) and the Integrated Biobank of
Luxembourg (IBBL, https://www.ibbl.lu), in accordance with
institutional guidelines. All human samples used in the scope of
this work were donated freely and written informed consent for
the use of the samples in research was obtained from the donors.
Ethical approval was obtained from the Comité National
d’Ethique de Recherche, Luxembourg (Reference 201009/09)
and from the institutional Ethics Review Panel (ERP-16-032).
Tissue microarray (TMA) blocks were prepared for 63 primary
CRC samples and paired normal colon counterparts, following
standard procedures [56]. Immunohistochemical staining was
performed on an automated Benchmark XT device (Ventana,
Tucson, AZ, USA) using the CC2 antigen retrieval solution (Cell
Conditioning 2, pH 8.4,) for 32–36 min. Following primary anti-
bodies were applied on serial sections: anti-HIF1A/HIF-1α rabbit
polyclonal antibody (LSBio, LS-B495) at 1:200 dilution, anti-
MAP1LC3B/LC3B rabbit polyclonal antibody (Sigma Aldrich,
HPA053767) at 1:500 dilution, and anti-p-EZR (Thr567)-
p-RDX/Radixin (Thr564)-p-MSN/Moesin (Thr558) (48G2) rabbit
monoclonal antibody (Cell Signaling Technology, 3726) at 1:100
dilution with an incubation time of 32 min. The same anti-BNIP3
and anti-BNIP3L antibodies as referred to in the western blot
paragraphwere also used. For the detection ofHIF1A, the primary
antibody OptiView DAB IHC detection kit was used, while for
p-EZR and LC3A, the UltraView DAB IHC detection kit
(Ventana) was used. Appropriate positive and negative controls
were included and kidney tissue was used as a positive control for
HIF1A staining.
For immunofluorescence staining, the following antibodies
were used: anti-MAP1LC3B (Cell Signaling Technology, 2775
and Santa Cruz Biotechnology, sc-271625), anti-BNIP3L (Cell
Signaling Technology, 12396), anti-CA9 (Invitrogen, MA5-
16318), p-ERM (3726S), and anti-POU5F1/OCT4
(Invitrogen, MA5-31458 and Abcam, ab18976). Fluorescence
stainings were carried out on 7 μm cryosections derived from
six human CRC samples (tumor stages 1 to 3) which were
fixed in acetone and stained with the indicated primary anti-
bodies. A mixture of goat anti-mouse IgG (Invitrogen, AF448,
A-10667) and donkey anti-rabbit IgG (Invitrogen, AF568,
A10042) was used as a secondary antibody. All antibodies
were used at a 1:200 dilution. Nuclei were visualized with
DAPI. Sections were mounted using fluorescent mounting
media (SouthernBiotech, 0100–20). For each patient, two
sections were visualized per staining. Pictures were acquired
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with the OLYMPUS IX83 microscope. Five regions per
patient were further analyzed and the fluorescence intensity
of each staining was measured using ImageJ (NIH). Sections
stained with only secondary antibodies were used as negative
controls. Correlation studies were carried out in order to
identify any potential colocalization of staining. To examine
co-staining in immunofluorescence sections, background-
corrected fluorescence intensities were standardized (z-score)
for each patient and antibody. A repeated measure correlation
was performed using the R environment (v3.6.0; https://www.
R-project.org/) and the R package rmcorr (v0.3.0 [57];).
P-values were adjusted for multiple testing using the Holm
method.
Cryosections (7 μm) of scramble and ATG5 knockdown
xenografts were prepared on a cryotome (Leica CM1850 UV
Cryostat). Sections were fixed in acetone and stained for
p-ERM (3726S) and donkey anti-rabbit IgG or only the sec-
ondary antibody control. Nuclei were visualized using DAPI.
Sections were mounted with fluorescent mounting media and
the resulting images were acquired with the OLYMPUS IX83
microscope. The positive area of each staining was deter-
mined by applying a threshold in ImageJ. Acquired data
were normalized to the average value of the scramble group.
Cell culture, hypoxic conditions, and reagents
Primary cultures T6, T18, and T20, which were established
from fresh patient material and fully characterized, were
maintained in spheroid culture (SC) conditions, as previously
described [19]. Adherent counterparts were cultivated in
DMEM-F12 (Lonza, BE12-719F), supplemented with 10%
fetal bovine serum (Thermo Fisher, 10270–106) and 100 U/
mL penicillin and streptomycin (Thermo Fisher, 15140122).
Throughout the study, hypoxia was achieved by maintain-
ing cells in a hypoxic incubator (Hera Cell 150, Thermo
Electron Corporation). For long-term cultures, cells were
maintained at 1% oxygen levels. For short-term cultures (pro-
tein time kinetics, phospho-protein arrays, and autophago-
some detection), 0.1% oxygen levels overnight (16 h) were
applied in a hypoxia chamber (Invivo2 400, Ruskinn).
Small inhibitors of EZR phosphorylation (BioConnect BV,
NSC 305787 and Fisher Scientific, NSC 668394) have been
described previously [32]. Blocking PKC was achieved by
using the chemical inhibitor Gö6976 (Calbiochem, CAS
136194-77-9).
Viral transductions
Ready-to-use lentiviral particles were used to generate spher-
oids with stable knockdowns of ATG5 (sc-41445-V), BECN1
(sc-29797-V), BNIP3 (sc-37451-V), BNIP3L (sc-37453-V),
HIF1A (sc-35561-V), and EZR (sc-35349-V) via short hairpin
RNA or respective control vectors (Santa Cruz
Biotechnology). Cells were transduced at a multiplicity of
infection (MOI) of 3–5 and selected for using puromycin
(Invivogen, ant-pr-1). Transduction efficiency was verified
via qPCR and western blot.
CRISPR/Cas9 lentiviral particles from Sigma Aldrich (for-
mat: [U6-gRNA/EF1a-puro-2A-Cas9-2A-GFP]) targeting
exon5 (HS 0000107120) or exon9 (HS0000107098) were
used to knock out EZR in TICs. Single clones were sequenced
to assess the genome editing.
Transient siRNA transfections
Dissociated spheroid cultures (SCs) were transfected for 48 h
according to the manufacturer’s instructions using the lipo-
fectamine RNAiMAX reagent (Life Technologies,13778150)
and a PRKCA-specific pool of four different siRNAs
(Qiagen, 1027416) or with a respective negative control
siRNA (Qiagen, 1027310). siRNA against EZR (Qiagen,
1027416 and Dharmacon, L-017370 and Acell Technology,
E-017370) was used according to the manufacturer’s protocol.
Sphere and 3D colony-formation assays
In vitro self-renewal capacity was tested with sphere formation
assays, as described previously [19]. Limiting dilution assays
were performed under SC conditions at different cell densities
(ranging from 1 to 1,000). The cells were incubated in hypoxic
or normoxic conditions for 7 d (sphere formation assays) or
10 d (limiting dilution assays). Afterward, both sphere num-
bers and sizes were measured under a microscope.
3D colony-formation assays were performed using a serum-
free mix of 60% SCM medium and 40% methylcellulose med-
ium, i.e. MethoCult® H4100 (StemCell Technologies, H4100),
supplemented with bFGF (Miltenyi Biotec, 130-093-841 20 ng/
mL) and EGF (Biomol, 50,349.5; 20 ng/mL). After 14 d, the
resulting 3D colonies were counted under a microscope.
In vivo tumor formation assays
NOD scid gamma (NSG) mice were bred in-house and
experiments were performed according to all applicable laws
and regulations, after receiving approval by the institution’s
animal experimentation ethics committee and the veterinarian
service of the Ministry of Agriculture (Permit Number: 14-
MDM-02). Tumor formation and in vivo self-renewal assays
(serial transplantations) were performed as previously
described [14]. Cells were taken up in 100 µL of growth
factor-reduced Matrigel (BD Biosciences, 356231) and subcu-
taneously injected in the flank of 8- to 10-week-old mice. To
assess the effect of CQ treatment on tumor growth, 10,000
cells were injected subcutaneously and CQ (60 mg/kg/d) or
PBS was administered via intra-peritoneal injections when
tumors were palpable. Tumor growth was calculated based
on the V = (π/6 × L × W × H) formula. The weight of resected
tumors was assessed at the endpoint of the experiment.
Autophagosome detection
Spheroids were transfected with an empty plasmid or a GFP-
LC3-encoding vector (kindly provided by N. Mizushima,
Tokyo Medical and Dental University, Tokyo) using the
Neon™ transfection system (Invitrogen) as described in
Noman et al. [58]. After 24 h of transfection, spheroids were
plated in µ-Slide eight-well chambered coverslips (IBIDI,
80816) and incubated under normoxic or hypoxic conditions
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for the following 24 h along with CQ (60 µM).
Autophagosomes were visualized in transfected normoxic
and hypoxic spheroids using an LSM-510-Meta confocal
microscope (Carl Zeiss).
Proliferation assay
Cells were dissociated and plated on regular 6-well plates at
a density of 80,000 cells in FBS (10%) and penicillin/strepto-
mycin (1%) supplemented DMEM-F12 for both normoxic
and hypoxic conditions. Cell confluence was assessed daily
using the IncuCyte FLR (Essen Bioscience).
CASP3 activity assay
Cells were plated in black 96-well µclear plates (Greiner,
655090) at a density of 20,000 per well. After 24 h, the cells
were lysed in 50 mM HEPES (Sigma-Aldrich, H0887) 1%
sucrose (Sigma, S0389), 0.1% CHAPS (Roth, 1479.3), 50 µM
Ac-DEVD-AFC (BioVision, 1007), 25 mM DTT, pH 7.5.
Fluorescence was then quantified using a microplate reader
(400 nm excitation and 505 nm emission, CLARIOstarR
[BMG-LABTECH]). As a positive control, cells were treated
with Staurosporine (20 µM; Sigma Aldrich, S4400). In addi-
tion, a synthetic tetrapeptide inhibitor for CASP3 (DEVD-
CHO, Alfa Aesar) was included in the assay as a negative
control for apoptosis.
TdT-mediated dUTP nick-end labeling (TUNEL) assay
TUNEL assays, allowing the detection of late apoptotic cells,
were performed using the DeadEnd™ Fluorometric TUNEL
System (Promega, G3250) according to the manufacturer’s
protocol. Spheres were briefly fixed via cytospins (EZ
Cytofunnels, Thermo Scientific) in 4% methanol-free formal-
dehyde diluted in PBS and permeabilized using Triton® X-100
(Sigma, T8787). After a pre-equilibration step, DNA strand
breaks were labeled with manufacturer-provided fluorescein-
12-dUTP (at 37°C for 1 h. Then, DAPI was added and the
localized green fluorescence of apoptotic cells was detected
using fluorescence microscopy.
Cell lysis and western blot analysis
Cell lysis and western blot analysis were carried out as pre-
viously described [14]. The following antibodies were used:
SQSTM1/p62 (8025), EZR/ezrin (3145S), ATG5 (2630S),
p-ERM (Thr567) (3726S), BNIP3 (13795S), BECN1/beclin-1
(3738S), p-MAPK14/p38 (4511), MAPK14/p38 (9212), p-AKT
(4060), p-MAPK/ERK (4370), p-PRKC/PKC (Ser660; 9371),
PRKCA/PKCα (2056), RDX/radixin (2636), and MSN/moesin
(3150) were all obtained from from Cell Signaling
Technology. AKT (sc-1619), MAPK3/ERK1 (sc-93),
MAPK1/ERK2 (sc-154), and tubulin alpha (TUBA/α-tubulin;
sc-32293) were purchased from Santa Cruz Biotechnology.
HIF1A/HIF-1α (610959) and ACTA1/actin (MAB1501) were
obtained from BD Bioscience and Merck Millipore, respec-
tively. All antibodies for WB were used at a dilution of 1:1000.
Secondary anti-mouse (7076S) and anti-rabbit (7074S) IgG
HRP-linked antibodies from Cell Signaling Technology were
used at a dilution of 1:5000. Chloroquine (60 μm; Sigma,
C6628) was added to normoxic and hypoxic samples in
order to study the autophagic flux.
Flow cytometry
Assessment of POU5F1/OCT4 levels and ALDH1A1 (alde-
hyde dehydrogenase 1 family member A1) detection was
carried out via flow cytometry on a FACSCanto II (BD
Biosciences). Cells were cultured at 1% O2 or normoxia for
48 h prior to analysis. POU5F1 expression was determined by
intracellular flow cytometry. Samples were fixed in 4% PFA in
PBS for 10 min, permeabilized using 0.01% saponin (Sigma,
S7900), and stained with an anti-POU5F1/OCT4 antibody
(Invitrogen, GT486) and a secondary goat anti-mouse anti-
body coupled to Alexa Fluor 488 (Invitrogen, A-10,667).
Samples stained with only the secondary antibody were uti-
lized as negative controls. All antibodies were used at a 1:100
dilution. ALDH1A1 activity assay was performed according to
the protocol provided by the manufacturer (ALDEFLUOR,
Stem Cell Technologies, 01700). Cell viability was assessed
by staining dead cells with Zombie NIR according to the
manufacturer’s protocol (BioLegend).
Real-time qPCR
RNA extractions, reverse transcriptions (RTs), and real-time
qPCRs were carried out according to previously reported
protocols [14]. Reference genes used for qPCR were:
EEF1A1 and YWHAZ. Primer pairs used for RT-qPCR are
listed in either Table S4 or described previously [19].
Gene expression profiling by microarrays
Microarray gene expression profiling experiments were per-
formed at the Luxembourg Institute of Health (LIH) and
were analyzed as previously described [19]. A false discovery
rate (FDR) < 0.05 and a |log2 fold change| > 1 were set as the
significance cutoff values for differentially expressed genes
(DEGs). Raw gene expression data are available from Array
Express under the following accession number: E-MTAB-
7354. DEGs were used to determine significantly deregulated
canonical pathways with Ingenuity Pathway Analysis (IPA,
Qiagen). Genes were mapped against five different autop-
hagy-relevant gene lists in order to verify the predicted
enrichment of the autophagic pathway in the different
patients. List 1 (autophagy database from [59] and the
Human Autophagy Database [HADb, {61}] provided by the
Luxembourg Institute of Health), List 2 (Autophagy gene list
provided by IPA including the database by Homma and
colleagues [59] and the HADb [60]), List 3 (autophagy
database by [59]), List 4 (HADb [60]), and List 5 (autophagy
gene list provided by IPA). Gene set enrichment analysis
(GSEA) was used to identify significantly deregulated
pathways.
14 K. QURESHI-BAIG ET AL.
Public datasets and survival analysis
The GSE14333 and GSE17538 datasets were used to assess
the association between BNIP3L expression and relapse-free
patient survival. “High” and “low” groups were separated at
the median gene expression value. Kaplan-Meier curves
were generated using the survival, ggplot2, and ggfortify
R packages.
Phosphorylation profiling
Phosphorylation profiling was carried out using the Phospho
Explorer Antibody Array, a high-throughput ELISA-based
antibody array (Full Moon Biosystems). This array consists
of 1318 antibodies (targeting proteins from over 30 signaling
pathways) and allows for the examination of tyrosine and
serine/threonine phosphorylation at specific sites. We used
this array to compare TICs under normoxia and hypoxia
(overnight, at 0.1% oxygen level), as well as ATG5-defective
TICs and corresponding control TICs cultured under
hypoxia. Cell pellets consisting of six million cells were sent
to Full Moon Biosystems for automated analysis. Fold change
expressions of below 0.5 and above 2 were used for the
identification of potential target phospho-proteins and for
subsequent validation experiments.
Statistical analysis
GraphPad Prism 5 software was used for statistical analysis.
Unpaired Student’s t-tests were used to compare the two
conditions and the two-way ANOVA test, along with Tukey
posttests, on log-transformed data, were used to compare
treatment effects in different groups and over time. All
experiments were performed in at least three independent
biological replicates and all associated data are reported as
mean ± SD, unless otherwise stated. The extreme limiting
dilution analysis software ELDA (http://bioinf.wehi.edu.au/
software/elda/) was used to determine the estimated stem
cell frequency for single-cell assays; the resulting self-
renewal capacity is reported as mean with 95% confidence
intervals (CI). Statistical analysis of in vivo experiments was
done using a 2-way ANOVA followed by post-hoc Tukey’s
multiple comparison tests.
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